Skip to main content
Premium Trial:

Request an Annual Quote

Zephyr AI Closes $18.5M Seed Round

NEW YORK – Bioinformatics startup Zephyr AI said Wednesday that it has completed an $18.5 million seed funding round. Lerner Group Investments and M-Cor Holdings led the round, with participation from AME Cloud Ventures, BoxGroup, MedStar Health, Verily, and several individual investors.

The Tysons Corner, Virginia-based company, has built a technology platform to aggregate, curate, and analyze multidimensional datasets with artificial intelligence to inform drug discovery and patient care. Zephyr AI draws its data from DNA mutations, copy number variants, gene expression, DNA-protein interactions, drug screening, electronic health records, medical imaging, and other sources.

Zephyr, founded a year ago by investment and incubation firm Red Cell Partners, will apply the new investment to further its goal of supporting precision medicine, particularly in diabetes and cancer care.

"This significant capital raise will help us expand our scope, including curating additional healthcare datasets, refining advanced machine-learning models, and deriving actionable insights for better outcomes in patient care and drug discovery," CEO David Morgan said in a statement.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.